维普期刊资源整合服务平台（V6.5）

维普中文期刊产品整合服务

13篇 您的检索式：作者名="TCHAMBAZ L"

选中清除导出查看参考文献查看引证文献引用追踪共1页首页上一页第1页下一页末页 /1 跳转

		题名	作者	年代	出处	被引量
	1	Prevalence of potentially severe drug-drug interactions in- ambulatory patients with dyslipidaemia receiving HMG-CoA reductase inhibitor therapy显示文摘	Ratz Bravo AE Tchambaz L Kr'ahenb'uhl-Melcher A	2005	Drug Saf2005，283，：	1
	2	Prevalence of potentially severe drug-drug interactions in ambulatory patients with dyslipidaemia receiving HMG-Co A reductase inhibitor therapy显示文摘	RATZ BRAVO AE TCHAMBAZ L KRAHENBUHL-ELCHER A	2005	Drug Saf2005，28，3：	1
	3	Prevalence of potentially severe drug-drug interactions in ambulatory patients with dyslipidaemia receiving HMG-CoA reductase inhibitor therapy 显示文摘	Rtz Bravo AE Tchambaz L Krihenbuhl-Melcher A	2005	Drug Saf2005，28，3：	1
	4	Prevalence of potentially severe drug-drug interaction in ambulatory patients with dyslipidaemia receiving HMG-CoA reductasc inhibitor therapy显示文摘	TRATZBRAVO A E TCHAMBAZ L KRAHENBUHLMELCHER A	2005	Drug Safe2005，28，3：	1
	5	Prevalence of potentially severe drug-drug interactions in ambulatory patients with dyslipidaemia receiving HMG-CoA reductase inhibitor therapy显示文摘	Ratz Bravo AE Tchambaz L Kr henbuhl-Melcher A	2005	Drug Saf2005，28，3：	1
	6	Prevalence of potentially severe drug-drug interactions in ambulatory patients with dyslipidaemia receiving HMG-CoA reductase inhibitor therapy显示文摘	Ratz Bravo AE Tchambaz L Krahenbuhl-Melcher A	2005	Drug Saf2005，28，3：	1
	7	Prevalence of potentially severe drug-drug interactions in ambulatory patients with dyslipidaemia receiving HMG-CoA reduetase inhibitor therapy显示文摘	RATZ BRAVO A E TCHAMBAZ L KR HENBEHL-MELCHER A	2005	Drug Saf2005，28，3：	1
	8	Prevalence of potentially severe drug-drug interaction in ambulatory patients with dyslipidaemia receiving HMG-GoA reductase inhibitor therapy显示文摘	Ratz Brabo AE Tchambaz L Krahenbuhl-Meicher A	2005	Drug Saf2005，28，3：	1
	9	Pharmacokinetic changes of psychotropic drugs in patients with liver disease: implications for dose adaptation显示文摘	Schlatter C Egger SS Tchambaz L	2009	Drug Saf2009，32，7：	1
	10	Dose adjustment in patients with liver disease 显示文摘	Delco F Tchambaz L Schlienger R	2005	Drug Saf2005，28，6：	1
	11	Prevalence of potentially severe drug-drug interaction in ambulatory patients with dyslipidaemia receiving HMG-CoA reductase inhibitor therapy显示文摘	RATZBRAVO AE TCHAMBAZ L KRAHENBUHL-MELCHER A	2005	Drug Saf2005，28，3：	1
	12	Prevalence of potentially severe drug-drug interactions in ambulatory patients with dyslipidaemia receiving HMG-CoA reduetase inhibitor therapy 显示文摘	Raztz Bravo AE Tchambaz L Krihenbilhl-Melcher A	2005	Drug Saf2005，28，3：	1
	13	Prevalence of potentially severe drug-drug interactions in ambulatory patients with dyslipidaemia receiving HMG-CoA reductase inhibitor therapy显示文摘	Ritz Bravo AE Tchambaz L Kr henb0hl-Melcher A	2005	Drug Saf2005，28，3：	1

返回顶部每页显示：

共1页首页上一页第1页下一页末页 /1 跳转

goolge学术搜索-维普

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1　渝公网安备 50019002500403号　违法和不良信息举报中心

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费